System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Shelley Zieroth is an expert in Cardiology at St. Boniface Hospital (Canada). As of October 2026, ScienceLeadR ranks Shelley Zieroth in the top 1% of experts worldwide for Heart Failure. Shelley Zieroth has authored 216 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 1 of them ongoing. SLR score: 1,157 (community average: 125). How the SLR is computed.

LeadR Profile

Shelley Zieroth St. Boniface Hospital Canada
1 157 ScienceLeadR Reputation 1157

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Endocrinology - Internal Medicine - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2013 - 2026
Source: PubMed

University of Manitoba

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 216

Citations

Citations: 14 733 1st author: 5 Last author: 31 Unique author: 0

Main journals

Can J Cardiol 43
J Card Fail 16
CJC Open 13
Eur J Heart Fail 12
Circulation 8

Best Journals

Circulation 7
Eur Heart J 7
N Engl J Med 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Obesity and Change in NT-proBNP with Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and a Worsening Heart Failure Event: PARAGLIDE-HF.
PMID 42863596 — valsartan, hospitalization, heart failure, heart, heart failure, diastolic, neprilysin, angiotensins, obesity		J Card Fail20260
Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
PMID 42667274 — cardiomyopathy, hypertrophic, therapeutics, blood circulation, cardiomyopathies		Circulation Top journal20261
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.
PMID 42663111 — exercise, heart failure, diastolic, cardiomyopathy, hypertrophic, cardiac myosins, therapeutics, blood circulation, cardiomyopathies		Circulation Top journal20261
ISN International Expert Forum: Exploring the Nexus of Cardiovascular-Kidney-Metabolic (CKM) Health.
PMID 42521017 — diabetes mellitus, kidney diseases, cardiovascular diseases, kidney, obesity, therapeutics		Kidney Int20261
Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.
PMID 42386047 — myocardial ischemia, heart diseases, heart, income, cardiology		Int J Cardiol20260

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 13
N/A 3

By status:

Completed 12
Unknown 2
Active not recruiting 1
Recruiting 1

By type:

Interventional 15
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 13

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894 — safety, multiple chronic conditions, tablets, cardiomyopathy, hypertrophic, cardiomyopathies		Phase 3Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS